Document is current

Article History

Received: 11 September 2021

Accepted: 5 May 2022

First Online: 16 May 2022

Declarations

:

: This retrospective study was approved by the ethics committee of Shiga University of Medical Science with R2020-037, which waived the need for written informed consent from the patients owing to the retrospective study design. All methods were carried out in accordance with the declaration of Helsinki.

: Not applicable.

: YU reports lecture fees from Ono Pharmaceutical, MSD, AstraZeneca, Chugai Pharma, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly, and Kyowa Hakko Kirin. DK reports lecture fees from AstraZeneca. YN reports lecture fees from Daiichi-Sankyo and Nippon Shinyaku. STM is an endowed chair from Kyowa Kirin and Eisai. HN reports lecture fees from Nippon Boehringer Ingelheim, Nippon Shinyaku, and AstraZeneca. KF reports lecture fees from Nippon Boehringer Ingelheim, Ono Pharmaceutical, Chugai Pharma, and AstraZeneca. MY reports lecture fees from AstraZeneca, Chugai Pharma, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, GlaxoSmithKline, Boston Scientific, Nippon Shinyaku, KYORIN Pharmaceutical, Novartis Pharma, TEIJIN, Sanofi, Ono Pharmaceutical, Bristol Myers Squibb, Astellas Pharma, MSD, Takeda Pharmaceutical, and Air Water Medical. YN reports lecture fees from AstraZeneca, Chugai Pharma, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, KYORIN Pharmaceutical, Novartis Pharma, Pfizer, Meiji Seika Kaisha, Nippon Kayaku, TEIJIN, and Otsuka Pharmaceutical, and advisor fee from Olympus. No other disclosures were reported.